These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 1537382)

  • 41. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
    Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
    J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccine.
    Chen KS; Burlington DB; Quinnan GV
    J Virol; 1987 Jul; 61(7):2150-4. PubMed ID: 3586130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice.
    Tamura S; Asanuma H; Ito Y; Yoshizawa K; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1994 Mar; 12(4):310-6. PubMed ID: 8178552
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.
    Tamura SI; Samegai Y; Kurata H; Kikuta K; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1989 Jun; 7(3):257-62. PubMed ID: 2781859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.
    Kikuta K; Hirabayashi Y; Nagamine T; Aizawa C; Ueno Y; Oya A; Kurata T; Tamura S
    Vaccine; 1990 Dec; 8(6):595-9. PubMed ID: 1965078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.
    Hirabayashi Y; Kurata H; Funato H; Nagamine T; Aizawa C; Tamura S; Shimada K; Kurata T
    Vaccine; 1990 Jun; 8(3):243-8. PubMed ID: 2363302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.
    Ikeda K; Ainai A; Hasegawa H
    Vaccine; 2015 Nov; 33(45):6066-9. PubMed ID: 26432916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.
    Musthaq SK; Kumar SR; Szyporta M; Kwang J
    Antiviral Res; 2014 Sep; 109():42-53. PubMed ID: 24973759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.
    Kadowaki S; Chen Z; Asanuma H; Aizawa C; Kurata T; Tamura S
    Vaccine; 2000 Jun; 18(25):2779-88. PubMed ID: 10812219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza.
    Tamura S; Funato H; Hirabayashi Y; Kikuta K; Suzuki Y; Nagamine T; Aizawa C; Nakagawa M; Kurata T
    Vaccine; 1990 Oct; 8(5):479-85. PubMed ID: 2251874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y; Xu YL; Lai YN; Liao SH; Liu N; Xu PP
    Phytomedicine; 2017 Oct; 34():127-135. PubMed ID: 28899494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
    Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
    J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments.
    Tamura S; Hasegawa H; Kurata T
    Jpn J Infect Dis; 2010 Jan; 63(1):8-15. PubMed ID: 20093755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration.
    Asanuma H; Koide F; Suzuki Y; Nagamine T; Aizawa C; Kurata T; Tamura S
    Vaccine; 1995 Jan; 13(1):3-5. PubMed ID: 7762274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.